Clinical Trial Detail

NCT ID NCT02921269
Title Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

cervix carcinoma

Therapies

Atezolizumab + Bevacizumab

Age Groups: senior adult

No variant requirements are available.